Clinical Analysis of 357 Cases of Systemic Lupus Erythematosus by First Diagnosis_West China Medical Journal

Authors：

 HEJin-chang , YUSu-jun , WEIWei , NAShi-li

Department of Rheumatology and Immunology, Panzhihua Central Hospital, Panzhihua City, Sichuan 617000, P. R. China;

Corresponding author：

Keywords：

Systemic lupus erythematosus; First diagnosis; Clinical manifestations; Laboratory test

DOI：

10.7507/1002-0179.20150196

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To analyze the clinical manifestations and laboratory test results of 357 cases of first-diagnosed systemic lupus erythematosus (SLE), and provide a reference for SLE diagnosis. Methods A total of 357 SLE patients on their first diagnosis were collected from 2008 to 2012 in our hospital, and the clinical manifestations and laboratory findings of these patients were recorded and analyzed. Results All the patients had different clinical manifestations and serious multi-system damages. In these patients, there were 59.1% (211 cases) involved with arthritis, followed by rash and kidney damage. The complement declined in 75.9% of the patients according to the results of immunological tests. In the ENA spectrum inspection, anti-SSA antibody had the highest positive rate (51.3%), followed by anti-u1RNP antibody (44.0%), anti-dsDNA antibody and anti-nucleosome antibody. The first onset of most clinical manifestations was rash (43.4%), followed by arthritis and lower extremity edema; a few patients had headache or numbness as the first symptom. Conclusion SLE patients have diverse clinical manifestations, serious multi-system damages and outstanding heterogeneity, which is inconsistent with foreign reports.

Citation： HEJin-chang, YUSu-jun, WEIWei, NAShi-li. Clinical Analysis of 357 Cases of Systemic Lupus Erythematosus by First Diagnosis. West China Medical Journal, 2015, 30(4): 685-687. doi: 10.7507/1002-0179.20150196 Copy

1.	Marian V, Anolik JH. Treatment targets in systemic lupus erythematosus:biology and clinical perspective[J]. Arthritis Res Ther, 2012, 14(Suppl 4):S3.
2.	陶洪群, 李小龙, 温怀凯, 等. 抗核小体抗体测定在系统性红斑狼疮中的意义[J]. 实用医学杂志, 2006, 22(3):338-339.
3.	Pathak S, Mohan C. Cellular and molecular pathogenesis of systemic lupus erythematosus:lessons from animal models[J]. Arthritis Res Ther, 2011, 13(5):241.
4.	Abdul-Sattar AB, Goda T, Negm MG. Neuropsychiatric manifestations in a consecutive cohort of systemic lupus erythematosus; a single center study[J]. Int J Rheum Dis, 2013, 16(6):715-723.
5.	Agarwal I, Kumar TS, Ranjini K, et al. Clinical features and outcome of systemic lupus erythematosus[J]. Indian Pediatr, 2009, 46(8):711-715.
6.	Mak A, Almsherqi ZA, Lai YW, et al. Intracellular tubulo reticular structures of peripheral blood mononuclear cells as an ultra-structural marker of disease activity in systemic lupus erythematosus:a pilot study[J]. Int J Rheum Dis, 2013, 16(6):692-697.
7.	李圣楠, 黄慈波. 系统性红斑狼疮的诊断治疗进展[J]. 临床药物治疗杂志, 2010, 8(1):6-10.
8.	Pérez Aceves E, Pérez Cristóbal M, Espinola Reyna GA, et al. Chronic respiratory disfunction due to diffuse alveolar hemorrhage in patients with systemic lupus erythematosus and primary vasculitis[J]. Reumatol Clin, 2013, 9(5):263-268.
9.	詹钟平, 梁柳琴, 陈冬莹, 等. 系统性红斑狼疮肺间质病变的临床特征[J]. 实用医学杂志, 2008, 24(22):3906-3907.
10.	Borchers AT, Keen CL, Shoenfeld Y, et al. Surviving the butterfly and the wolf:mortality trends in systemic lupus erythematosus[J]. Autoimmun Rev, 2004, 3(6):423-453.
11.	Mok CC, Lee KW, Ho CT, et al. A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population[J]. Rheumatology, 2000, 39(4):399-406.
12.	Smolen JS. Therapy of systemic lupus erythematosus:a look into the future[J]. Arthritis Res, 2002, 4(Suppl 3):S25-S30.
13.	Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus[J]. Circulation, 2012, 126(1):76-82.
14.	Jorge Asano NM, Wanderley De Sales Coriolano MD, Asano BJ, et al. Psychiatric comorbidities in patients with systemic lupus erythematosus:a systematic review of the last 10 years[J]. Rev Bras Reumatol, 2013, 53(5):431-437.
15.	Amaya-Amaya J, Sarmiento-Monroy JC, Caro-Moreno J, et al. Cardiovascular disease in latin american patients with systemic lupus erythematosus:a cross-sectional study and a systematic review[J]. Autoimmune Dis, 2013:794383.

1. Marian V, Anolik JH. Treatment targets in systemic lupus erythematosus:biology and clinical perspective[J]. Arthritis Res Ther, 2012, 14(Suppl 4):S3.
2. 陶洪群, 李小龙, 温怀凯, 等. 抗核小体抗体测定在系统性红斑狼疮中的意义[J]. 实用医学杂志, 2006, 22(3):338-339.
3. Pathak S, Mohan C. Cellular and molecular pathogenesis of systemic lupus erythematosus:lessons from animal models[J]. Arthritis Res Ther, 2011, 13(5):241.
4. Abdul-Sattar AB, Goda T, Negm MG. Neuropsychiatric manifestations in a consecutive cohort of systemic lupus erythematosus; a single center study[J]. Int J Rheum Dis, 2013, 16(6):715-723.
5. Agarwal I, Kumar TS, Ranjini K, et al. Clinical features and outcome of systemic lupus erythematosus[J]. Indian Pediatr, 2009, 46(8):711-715.
6. Mak A, Almsherqi ZA, Lai YW, et al. Intracellular tubulo reticular structures of peripheral blood mononuclear cells as an ultra-structural marker of disease activity in systemic lupus erythematosus:a pilot study[J]. Int J Rheum Dis, 2013, 16(6):692-697.
7. 李圣楠, 黄慈波. 系统性红斑狼疮的诊断治疗进展[J]. 临床药物治疗杂志, 2010, 8(1):6-10.
8. Pérez Aceves E, Pérez Cristóbal M, Espinola Reyna GA, et al. Chronic respiratory disfunction due to diffuse alveolar hemorrhage in patients with systemic lupus erythematosus and primary vasculitis[J]. Reumatol Clin, 2013, 9(5):263-268.
9. 詹钟平, 梁柳琴, 陈冬莹, 等. 系统性红斑狼疮肺间质病变的临床特征[J]. 实用医学杂志, 2008, 24(22):3906-3907.
10. Borchers AT, Keen CL, Shoenfeld Y, et al. Surviving the butterfly and the wolf:mortality trends in systemic lupus erythematosus[J]. Autoimmun Rev, 2004, 3(6):423-453.
11. Mok CC, Lee KW, Ho CT, et al. A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population[J]. Rheumatology, 2000, 39(4):399-406.
12. Smolen JS. Therapy of systemic lupus erythematosus:a look into the future[J]. Arthritis Res, 2002, 4(Suppl 3):S25-S30.
13. Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus[J]. Circulation, 2012, 126(1):76-82.
14. Jorge Asano NM, Wanderley De Sales Coriolano MD, Asano BJ, et al. Psychiatric comorbidities in patients with systemic lupus erythematosus:a systematic review of the last 10 years[J]. Rev Bras Reumatol, 2013, 53(5):431-437.
15. Amaya-Amaya J, Sarmiento-Monroy JC, Caro-Moreno J, et al. Cardiovascular disease in latin american patients with systemic lupus erythematosus:a cross-sectional study and a systematic review[J]. Autoimmune Dis, 2013:794383.

West China Medical Journal

Clinical Analysis of 357 Cases of Systemic Lupus Erythematosus by First Diagnosis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content